How Do Intimate Partner Violence, Outness, and Community Connection Relate to Minority Stressors for Men Who Have Sex with Men?

Intimate partner violence (IPV) is a pervasive issue among men who have sex with men (MSM). However, IPV has long been conceptualized as abuse between a male perpetrator and a female victim, leaving gaps in the literature on the unique impacts IPV victimization has for both male victims and victims in same-sex relationships. This study examines relationships between IPV and negative minority stress experiences specific to LGBTQ individuals: overt experiences of homophobia, sexual orientation microaggressions, and internalized homophobia.

"He gets mad that I'm sober": Experiences of substance use coercion among postpartum women in recovery.

Purpose: The number of women with substance use disorders (SUDs) is growing in the U.S. Many women with SUDs are of childbearing age, and studies show that women who abstain from substance use during pregnancy often relapse in the postpartum period.

"They Knew They Were Still Safe with Us": Experiences of Domestic Violence Shelter Staff on Survivors' Experiences in Shelter in the Early COVID-19 Pandemic.

Background: Domestic violence (DV) shelters are an essential service for survivors and their children. While research has demonstrated global increases in DV during COVID-19, little is known about the experiences of DV shelter staff. This study aimed to understand DV shelter staff's experiences and how they navigated the early stages of the pandemic.

Reproductive Coercion in Heterosexual and Sexual Minority Emerging Adults: Prevalence and Behavioral Health Impact.

Reproductive coercion (RC) is a type of intimate partner violence (IPV) characterized by partner interference with contraception or reproductive decision-making. Despite sexual minority people's vulnerability to other forms of IPV, limited research has examined reproductive coercion in this population. Research on behavioral health impacts of reproductive coercion is also lacking, especially for sexual minorities.

SOM230: a new therapeutic modality for Cushing's disease.

A rational drug design approach involving transposition of functional groups from SRIF into a reduced size cyclohexapeptide template has led to the discovery of SOM230, a novel, stable cyclohexapeptide somatostatin mimic which exhibits unique high affinity binding to human somatostatin receptors (sst1-5). This unique receptor subtype binding profile, in particular the exceptional high affinity binding to sst5, led to SOM230 being approved by EMEA and FDA in 2012 as the first effective pituitary directed therapeutic modality for Cushing's disease.